Antibody Drug Conjugates ADCs

ADCs propelled back into the oncology spotlight

Monday 14 November 2011

Interviewee/Contributer: Karen Finn

Organisation: MedNous

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Why Oxford BioTherapeutics is targeting ADCs

Sunday 13 November 2011

Interviewee/Contributer: Christian Rohlff

Organisation: Oxford BioTherapeutics Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

How developers approach antibody drug conjugates

Saturday 12 November 2011

Interviewee/Contributer: Bruno Pagliara

Organisation: On-kòs Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content